Abstract
Introduction and hypothesis
The association between overactive bladder (OAB) syndrome and sexual dysfunction is well documented. Intra-detrusor onabotulinumtoxinA (Botox) has proven to be effective treatment for OAB syndrome. Our aim was to examine the impact of intravesical Botox injection on sexual function in patients with OAB, by systematically reviewing the literature.
Methods
We reviewed the literature for studies that reported a change in sexual function after Botox treatment in patients suffering from OAB. This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement using pre-agreed keywords, from database inception to December 2020. Statistical analyses were performed using Review Manager (RevMan; v.5.4).
Results
Initial results yielded 455 citations. Seven articles met our inclusion criteria. One article was double-reported, leaving 6 studies in the systematic review. Three observational before-and-after studies used the Female Sexual Function Index (FSFI) with sufficient information, and therefore were included in our meta-analysis. The pooled number of participants in all studies was 119 patients. In the meta-analysis, there was significant improvement in the following domains of the FSFI after Botox injection; desire (mean difference (MD) −0.51, p = 0.02), arousal (MD −0.86, p = 0.02), lubrication (MD −0.57, p = 0.03), orgasm (MD −0.65, p = 0.0003) and satisfaction (MD −0.46, p = 0.05). Pain was the only domain that did not show improvement (MD −0.07, p = 0.79). The total FSFI score was reported in 88 patients (two studies) showing significant improvement (MD −0.77, p = 0.006).
Conclusions
We report a systematic review of the effect of Botox treatment on sexual function in patients with OAB. Although studies are small, the results indicate a positive effect in patients with OAB.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig5_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig6_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig7_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00192-021-05072-7/MediaObjects/192_2021_5072_Fig8_HTML.png)
Similar content being viewed by others
References
Abrams P, Andersson KE, Birder L, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40. https://doi.org/10.1002/nau.20870.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 1314–5. https://doi.org/10.1016/j.eururo.2006.09.019.
Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.
Perry S, McGrother CW, Turner K, Leicestershire MRC Incontinence Study Group. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol. 2006;11(Pt 3):463–82. https://doi.org/10.1348/135910705X60742.
Sen I, Onaran M, Tan MO, Acar C, Camtosun A, Sozen S, Bozkirli I. Evaluation of sexual function in women with overactive bladder syndrome. Urol Int. 2007;78(2):112–5. https://doi.org/10.1159/000098066.
Patel AS, O'Leary ML, Stein RJ, Leng WW, Chancellor MB, Patel SG, Borello-France D. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006;32(1):77–87. https://doi.org/10.1590/s1677-55382006000100014.
Zahariou A, Karamouti M, Tyligada E, Papaioannou P. Sexual function in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2010;16(1):31–6. https://doi.org/10.1097/SPV.0b013e3181bf51eb.
Jha S, Ammenbal M, Metwally M. Impact of incontinence surgery on sexual function: a systematic review and meta-analysis. J Sex Med. 2012;9(1):34–43. https://doi.org/10.1111/j.1743-6109.2011.02366.x.
López Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodríguez A, Moreno Bencardino C. Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis. Urology. 2017;100:53–8. https://doi.org/10.1016/j.urology.2016.10.026.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.
Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.
Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.
Giannantoni A, Gubbiotti M, et al. Effects of Onabotulinum toxin a intradetrusor injections on urinary symptoms and sexual life in women affected by multiple sclerosis: a prospective controlled study. J Neurol Neurophysiol. 2017;8(3):1000427. https://doi.org/10.4172/2155-9562.1000427.
Giannantoni A, Proietti S, Giusti G, et al. OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. World J Urol. 2015;33(12):2095–101. https://doi.org/10.1007/s00345-015-1578-4.
Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. https://doi.org/10.1016/j.juro.2012.12.022.
Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. https://doi.org/10.1016/j.eururo.2013.04.001.
Fowler CJ, Auerbach S, Ginsberg D, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57. https://doi.org/10.1016/j.eururo.2012.03.005.
Balzarro M, Rubilotta E, Braga A, et al. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228–31. https://doi.org/10.1016/j.ejogrb.2018.05.002.
Miotla P, Cartwright R, Skorupska K, et al. Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. Neurourol Urodyn. 2017;36(6):1564–9. https://doi.org/10.1002/nau.23148.
Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208. https://doi.org/10.1080/009262300278597.
Balzarro M, Rubilotta E, Mancini V, et al. Impact of overactive bladder-wet syndrome on female sexual function: a systematic review and meta-analysis. Sex Med Rev. 2019;7(4):565–74. https://doi.org/10.1016/j.sxmr.2019.05.002.
Levy G, Lowenstein L. Overactive bladder syndrome treatments and their effect on female sexual function: a review. Sex Med. 2020;8(1):1–7. https://doi.org/10.1016/j.esxm.2019.08.013.
Zachariou A, Mamoulakis C, Filiponi M, et al. The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urol. 2018;18(1):61. https://doi.org/10.1186/s12894-018-0377-9.
Del Rosso A, Pace G, Di Pierro ED, Masciovecchio S, Galatioto GP, Vicentini C. Impact of overactive bladder on sexual function in women. Urologia. 2011;78(3):200–2. https://doi.org/10.5301/RU.2011.8547.
Cakir SS, Degirmentepe RB, Atalay HA, et al. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. Int Urol Nephrol. 2019;51(1):27–32. https://doi.org/10.1007/s11255-018-2030-7.
Zachariou A, Filiponi M. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Int Braz J Urol. 2017;43(4):713–20. https://doi.org/10.1590/S1677-5538.IBJU.2016.0303.
Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54. https://doi.org/10.1111/bju.12972.
Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature. Int Urogynecol J. 2019;30(3):339–52. https://doi.org/10.1007/s00192-018-3841-x.
Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16. https://doi.org/10.1002/nau.22251.
Kershaw V, Khunda A, McCormick C, Ballard P. The effect of percutaneous tibial nerve stimulation (PTNS) on sexual function: a systematic review and meta-analysis. Int Urogynecol J. 2019;30(10):1619–27. https://doi.org/10.1007/s00192-019-04027-3.
Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol. 2018;132(2):453–8. https://doi.org/10.1097/AOG.0000000000002733.
Acknowledgements
We are grateful for the help and support provided by Heba Shawer in the editing and revision of this review and for Mrs. Carol McCormick for help with the literature search.
Funding
No external funding was used for this systematic review and meta-analysis.
Author information
Authors and Affiliations
Contributions
Sami Shawer: project development, data collection and analysis, manuscript writing; Aethele Khunda: project development, data collection, revision of the manuscript, overall supervision, and final approval; Gareth J. Waring: project development, revision of the manuscript and supervision; Paul Ballard: supervision of the project and final approval.
Corresponding author
Ethics declarations
Conflicts of interest
Sami Shawer: no conflicts of interest; Aethele Khunda: in the last 5 years, received educational grants from Medtronic, Olympus, Axonic and speaker fees from Astellas (I also received travel and accommodation expenses from conference organisers when invited as a speaker); Gareth J. Waring: no conflicts of interest; Paul Ballard: in the last 5 years, received an educational grant from Olympus.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shawer, S., Khunda, A., Waring, G.J. et al. Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J 33, 235–243 (2022). https://doi.org/10.1007/s00192-021-05072-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-021-05072-7